Johnson Philip L 4

What Happened

• Philip L. Johnson, Chief Financial Officer of Jazz Pharmaceuticals plc, had 3,343 ordinary shares withheld on June 30, 2026 to satisfy tax obligations related to the vesting of previously granted restricted stock units (RSUs). The withheld shares are reported as a disposition at $237.72 per share, totaling approximately $794,698. This is a tax-withholding/net settlement action, not an open-market sale.

Key Details

• Transaction date: 2026-06-30; Price per share: $237.72; Shares withheld/disposed: 3,343; Total value ≈ $794,698.
• Transaction code: F — tax withholding (shares withheld to satisfy tax obligations from RSU vesting).
• Footnote F1: Confirms shares were withheld to satisfy tax obligations arising from vesting of RSUs.
• Footnote F2: Separately, the reporting person acquired 166 ordinary shares under the company’s Section 423 Employee Stock Purchase Plan on May 29, 2026.
• Filing: Form filed 2026-07-02 (appears timely — Form 4 is generally due within two business days of the transaction).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• This transaction is a routine net-settlement/tax-withholding event tied to RSU vesting and does not represent a discretionary market sale or a purchase signal. Such withholdings are common when executives receive vested equity and are required to cover associated taxes. The small ESPP purchase noted in the footnote is a typical employee purchase and is modest in size.